Glenmark Pharmaceuticals became the first to launch Thiazolidinedione Lobeglitazone Lobeglitazone in India for the treatment of type 2 diabetes in adults Marketed under the brand name LOBG; it contains Lobeglitazone 05 mg and to be taken once daily under prescription to improve glycemic control in adult diabetic patients Indians have a high prevalence of insulin resistance and that makes LOBG an appealing treatment option in managing uncontrolled Type 2 diabetes among insulin]resistant diabetic patients Glenmark earlier received approval from the Indian drug regulator Drug Controller General of India for manufacturing and marketing Lobeglitazone based on a randomized double]blind Phase 3 clinical trial conducted on adult Type 2 diabetic patients aged 18 years and older The results of this trial have shown a faster and improved glycemic control with Lobeglitazone
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
